SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Share News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.55    0.00 (0.00%)
Bid:
1.60
Ask:
1.90
Spread: 0.30 (18.75%)
Market Cap: £5.44m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Proteome Sciences reports solid growth in 2022

Tue, 04th Apr 2023 11:44

(Sharecast News) - Biotechnology company Proteome Sciences reported total revenues of £7.78m in its final results on Tuesday - a significant year-on-year increase from £5.13m.

The AIM-traded firm said the revenue growth was driven by an increase in proteomic biomarker service revenues, from £1.9m to £2.75m, and 'TMT' sales, royalties and milestones, from £3.23m to £5.03m.

It reported total costs for 2022 of £6.05m, up from £4.72m in the prior year.

However, the company's EBITDA still increased to £2.13m from £0.63m.

The board said adjusted EBITDA also showed an increase, to £2.43m from £1.35m year-on-year.

Proteome reported a profit after tax of £1.33m, surging from £0.07m in 2021.

The firm's cash reserves at the end of the year totalled £3.99m, up from £2.39m a year earlier.

"We have continued to show strong growth of our revenues, both in service sales and the TMT business despite the backdrop of negative external factors, mainly the Russia-Ukraine war and its global impact on supply chains, energy prices, inflation rates and economic recessions," said chief executive officer Mariola Soehngen.

"The milestone we earned based on cumulative sales at Thermo Scientific contributed to this positive development.

"EBITDA increased mainly due to increased revenues, and including the sales milestone payment of £0.87m received from Thermo Scientific."

Dr Soehngen said the company had continued to strategically invest in its workforce and instruments, by hiring six employees and adding various instruments to support the promotion of new services, including the 'CellenONE' single cell proteomics (SCP) platform, and made investments into new reagents as future value drivers of its tag business.

"We are looking forward to the SCP product launch later in the year and remain confident of being one of the first contract research organisations providing a high-performance SCP service.

"The new tag development programmes already meet high interest in the market."

At 1013 BST, shares in Proteome Sciences were down 1.11% at 3.56p.

Reporting by Josh White for Sharecast.com.

Related News

WINNERS & LOSERS: Aeorema wins climate event deal; RWS cuts dividend
3 days ago

WINNERS & LOSERS: Aeorema wins climate event deal; RWS cuts dividend

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday.

EXECUTIVE CHANGES: Victoria doesn't replace CEO; all change at eEnergy
5 Jun 2026

EXECUTIVE CHANGES: Victoria doesn't replace CEO; all change at eEnergy

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced this week and not separately reported by...

WINNERS & LOSERS: Marechale rallies on digital bank plan; boohoo jumps
3 Jun 2026

WINNERS & LOSERS: Marechale rallies on digital bank plan; boohoo jumps

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Wednesday.

Proteome News

WINNERS & LOSERS: Aeorema wins climate event deal; RWS cuts dividend
3 days ago

WINNERS & LOSERS: Aeorema wins climate event deal; RWS cuts dividend

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday.

EXECUTIVE CHANGES: Victoria doesn't replace CEO; all change at eEnergy
5 Jun 2026

EXECUTIVE CHANGES: Victoria doesn't replace CEO; all change at eEnergy

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced this week and not separately reported by...

WINNERS & LOSERS: Marechale rallies on digital bank plan; boohoo jumps
3 Jun 2026

WINNERS & LOSERS: Marechale rallies on digital bank plan; boohoo jumps

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Wednesday.

WINNERS & LOSERS: Gelion agrees to collaboration; Sabien receives fees
2 Jun 2026

WINNERS & LOSERS: Gelion agrees to collaboration; Sabien receives fees

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.

WINNERS & LOSERS: GSTechnologies wins ruling; RentGuarantor revenue up
1 Jun 2026

WINNERS & LOSERS: GSTechnologies wins ruling; RentGuarantor revenue up

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Friday.

WINNERS & LOSERS: Hamak jumps on gold data; MicroSalt cuts sales guide
28 May 2026

WINNERS & LOSERS: Hamak jumps on gold data; MicroSalt cuts sales guide

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday.

WINNERS & LOSERS: Indonesia curbs hit MP Evans; S&U rises
20 May 2026

WINNERS & LOSERS: Indonesia curbs hit MP Evans; S&U rises

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Wednesday.

WINNERS & LOSERS: Advanced Medical suitor walks away; Capita climbs
18 May 2026

WINNERS & LOSERS: Advanced Medical suitor walks away; Capita climbs

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Monday.